India liver cancer therapeutics market is
anticipated to witness impressive growth during the forecast period. This can
be ascribed due to the rising occurrence of liver cancer. The incidence of
liver cancer in India has been steadily rising over the past few decades, with
risk factors such as chronic viral hepatitis, alcohol abuse, and non-alcoholic
fatty liver disease contributing to the increasing burden of the disease.
Advances in medical technology have led to the development of new and more
effective treatments for liver cancer, including targeted therapies and
immunotherapies, which have significantly improved patient outcomes. Early
detection and treatment are critical to improving outcomes for liver cancer
patients. As awareness of the disease and the importance of early detection
continues to grow, more people are seeking medical attention and receiving
timely diagnosis and treatment. The Indian government has been increasing its
healthcare spending in recent years, which has led to greater access to medical
care and improved patient outcomes. This has contributed to the growth of the
liver cancer therapeutics market by enabling more patients to receive timely
and effective treatment. Public health initiatives, including awareness
campaigns and screening programs, have played a crucial role in increasing
awareness about the importance of early diagnosis and treatment for liver
cancer. Several healthcare organizations and advocacy groups have also been
working to improve access to screening and treatment options for liver cancer
patients. There has been shift toward personalized medicine as personalized
medicines involve tailoring treatment to an individual's specific genetic and
molecular characteristics.
Rising Cases of Cirrhosis
Cirrhosis is a condition where the liver becomes
scarred and damaged over time, often due to chronic alcohol abuse, viral
hepatitis, or other liver diseases. The damage to the liver cells caused by
cirrhosis can lead to the development of liver cancer over time. Cirrhosis can increase
the risk of liver cancer in several ways. Firstly, the scar tissue that forms
in the liver can disrupt normal liver function and make it more difficult for
the liver to remove toxins and other harmful substances from the body. This can
increase the risk of DNA damage and mutations that can lead to the development
of liver cancer. Secondly, cirrhosis can increase the risk of chronic
inflammation in the liver, which can further damage liver cells and increase
the risk of liver cancer. This is because chronic inflammation can lead to the
formation of scar tissue and the activation of signaling pathways that promote
the growth and survival of cancer cells. Thirdly, people with cirrhosis may be
more likely to have a history of other risk factors for liver cancer, such as
chronic viral hepatitis, alcohol abuse, or exposure to environmental toxins.
Thus, cirrhosis is a significant risk factor for the development of liver
cancer, and people with cirrhosis should undergo regular medical check-ups and
screenings. Such factors will drive the growth of the India liver cancer
therapeutics market during the forecast period.
Development in Medical Technology
There have been several advancements in liver
cancer therapeutics in recent years. Some of these advancements include
targeted therapies. These therapies are drugs that are designed to specifically
target cancer cells while sparing healthy cells. There are several targeted
therapies approved for the treatment of liver cancer, including sorafenib,
regorafenib, and lenvatini. Immunotherapy is a type of treatment that uses the
body's own immune system to fight cancer. Immune checkpoint inhibitors, such as
nivolumab and pembrolizumab, have been approved for the treatment of liver
cancer. Combination therapies involve using multiple drugs or treatment
modalities to treat cancer. Several combination therapies have been approved
for the treatment of liver cancer, including the combination of atezolizumab
and bevacizumab. Surgical techniques for liver cancer have improved in recent
years, including the use of laparoscopic and robotic surgeries. Laparoscopic
and robotic surgeries have become increasingly popular in the treatment of
liver cancer in India. These minimally invasive surgical techniques offer
several benefits over traditional open surgeries, including smaller incisions,
less pain and scarring, faster recovery times, and reduced risk of
complications. In laparoscopic surgery, the surgeon makes several small
incisions in the abdomen and inserts a laparoscope (a thin, flexible tube with
a camera and light) and surgical instruments to remove the tumor. In robotic
surgery, the surgeon uses a robotic system to control the surgical instruments
and perform the surgery.
Personalized medicines involve tailoring treatment
to an individual's specific genetic and molecular characteristics. Advances in
genomic testing have allowed for the identification of specific genetic
mutations in liver cancer, which can help guide treatment decisions. Such
factors will accelerate the growth of the India liver cancer therapeutic market
during the forecast period.
Increment in Healthcare Expenditure
As liver cancer is a serious health issue and
requires specialized medical care, the cost of treatment can be significant.
Therefore, an increase in healthcare expenditure can lead to increased access
to medical care for patients with liver cancer, which can help to boost the
demand for liver cancer therapeutics in India. Moreover, the Government of
India has launched various healthcare initiatives and schemes, such as the
Ayushman Bharat scheme, which aims to provide affordable and accessible
healthcare to all citizens. Such initiatives and schemes can further boost the
demand for liver cancer therapeutics in India, leading to market growth. National
Cancer Grid is a network of cancer centers, research institutes, and
universities that collaborate to provide standardized cancer care in India. The
National Cancer Grid aims to improve the quality of cancer care, including
liver cancer, by promoting research, training, and sharing best practices. Make
in India aims to promote domestic manufacturing of medical devices and
pharmaceuticals in India, including liver cancer therapeutics. By promoting
local manufacturing, the initiative aims to reduce the cost of cancer treatment
and improve access to affordable liver cancer therapeutics for patients. These
initiatives aim to increase access to medical care, improve the quality of
cancer care, reduce the cost of cancer treatment, and play a vital role in driving
the growth of the India liver cancer therapeutics market.
Download Free Sample Report
Recent Development
In 2021, Cadila Healthcare Ltd. announced that it
had received tentative approval from the US FDA for its abbreviated new drug
application (ANDA) for Tenofovir Disoproxil Fumarate (TDF) tablets used in the
treatment of chronic hepatitis B virus infection.
In 2021, Biocon Ltd. announced that it had received
approval from the Drug Controller General of India (DCGI) to market its
biosimilar version of bevacizumab, used in the treatment of multiple types of
cancer, including liver cancer.
In 2020, Dr. Reddy's Laboratories Ltd. announced a
collaboration with Bioclinica, Inc. to conduct clinical trials for liver cancer
therapeutics.
In 2018, Cipla Ltd. announced the launch of its
generic version of sorafenib tosylate, under the brand name Soranib, for the
treatment of liver cancer.
In 2017, Sun Pharmaceutical Industries Ltd.
acquired Swiss-based oncology drug maker Pola Pharma Inc., which has a
portfolio of products for the treatment of liver cancer.
Market Segmentation
The India liver cancer therapeutics market can be
segmented by cancer type, therapy, route of administration, distribution
channel, and region. By cancer type, the market can be segmented into
hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, and
liver metastasis. By therapy, the market can be segmented into targeted
therapy, chemotherapy and radiation therapy, immunotherapy, and others. By
route of administration, the market can be segmented into oral, intravenous,
and others. By distribution channel, the market can be segmented into hospital
pharmacies, retail pharmacies, and online pharmacies. By region, the market can
be segmented into North India, South India, East India, and West India.
Market Players
Natco Pharma Ltd., Dr. Reddy's Laboratories Ltd.,
Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Pvt. Ltd., Lupin Ltd., Biocon
Ltd., and Hetero Labs Ltd. are some of the market players in the India liver
cancer therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2023
|
|
Historic Data
|
2019 – 2022
|
|
Estimated Year
|
2024
|
|
Forecast Period
|
2025 – 2029
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2023
and 2024-2029
|
|
Report Coverage
|
Revenue forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments Covered
|
Cancer Type
Therapy
Route of Administration
Distribution Channel
|
|
Regional scope
|
North India, South India, East India, West India
|
|
Key companies profiled
|
Natco Pharma Ltd., Dr. Reddy's
Laboratories Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Pvt.
Ltd., Lupin Ltd., Biocon Ltd., Hetero Labs Ltd.
|
|
Customization scope
|
10% free report customization with purchase. Addition or alteration to
country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to
meet your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the editable version
of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the India liver cancer therapeutics
market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- India Liver Cancer TherapeuticsMarket, By
Cancer Type:
o Hepatocellular
Carcinoma
o Cholangiocarcinoma
o Hepatoblastoma
o Angiosarcoma
o Liver
Metastasis
- India Liver Cancer TherapeuticsMarket, By
Therapy:
o Targeted
Therapy
o Chemotherapy
& Radiation Therapy
o Immunotherapy
o Others
- India Liver Cancer TherapeuticsMarket, By
Route of Administration:
o Oral
o Intravenous
o Others
- India Liver Cancer TherapeuticsMarket, By
Distribution Channel:
o Hospital
Pharmacies
o Retail
Pharmacies
o Online
Pharmacies
- IndiaLiver Cancer TherapeuticsMarket, By
Region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company Profiles: Detailed analysis of
the major companies present in the India liver cancer therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India liver cancer therapeutics market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]